Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas
D Cappellen, C De Oliveira, D Ricol, S de Medina… - Nature …, 1999 - nature.com
D Cappellen, C De Oliveira, D Ricol, S de Medina, J Bourdin, X Sastre-Garau, D Chopin…
Nature genetics, 1999•nature.comTumour stage was defined using TNM and FIGO classifications for bladder and cervix
carcinomas, respectively; Mostofi's histopathological grading system was used for bladder
cancer; codon and mutated nucleotide (nt position) are numbered according to FGFR3b
cDNA ORF. All mutations were identified in both cDNA and genomic DNA from bladder and
cervix tumours. For all bladder tumour cases, non-tumour genomic DNA was tested and
found to be wild type. Corresponding normal DNAs were not available for cervix tumours.
carcinomas, respectively; Mostofi's histopathological grading system was used for bladder
cancer; codon and mutated nucleotide (nt position) are numbered according to FGFR3b
cDNA ORF. All mutations were identified in both cDNA and genomic DNA from bladder and
cervix tumours. For all bladder tumour cases, non-tumour genomic DNA was tested and
found to be wild type. Corresponding normal DNAs were not available for cervix tumours.
Tumour stage was defined using TNM and FIGO classifications for bladder and cervix carcinomas, respectively; Mostofi’s histopathological grading system was used for bladder cancer; codon and mutated nucleotide (nt position) are numbered according to FGFR3b cDNA ORF. All mutations were identified in both cDNA and genomic DNA from bladder and cervix tumours. For all bladder tumour cases, non-tumour genomic DNA was tested and found to be wild type. Corresponding normal DNAs were not available for cervix tumours.
nature.com